Emerging role of endothelin-1 in tumor angiogenesis

Trends in Endocrinology and Metabolism

Volumn 14, Issue 1, 2003, Pages 44-50

  Bagnato, Anna ^a   Spinella, Francesca ^a  

^a REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; CHELATING AGENT; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); CYCLOHEXIMIDE; CYTOKINE; ENDOTHELIN 1; ENDOTHELIN A RECEPTOR; ENDOTHELIN A RECEPTOR ANTAGONIST; ENDOTHELIN B RECEPTOR; FOCAL ADHESION KINASE; G PROTEIN COUPLED RECEPTOR; GELATINASE A; GROWTH FACTOR; HYPOXIA INDUCIBLE FACTOR 1ALPHA; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; NITRIC OXIDE; PHOSPHORAMIDON; PROTEINASE; SCLEROPROTEIN; TRANSITION ELEMENT; TYROSINE KINASE RECEPTOR; VASCULOTROPIN;

ANGIOGENESIS; EXTRACELLULAR MATRIX; HUMAN; NONHUMAN; OVARY CARCINOMA; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION;

ANIMALS; DNA-BINDING PROTEINS; ENDOTHELIAL GROWTH FACTORS; ENDOTHELIN-1; HUMANS; HYPOXIA-INDUCIBLE FACTOR 1; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; LYMPHOKINES; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; NUCLEAR PROTEINS; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RECEPTORS, ENDOTHELIN; SIGNAL TRANSDUCTION; TRANSCRIPTION FACTORS; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0038407691     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1043-2760(02)00010-3     Document Type: Review

References (64)

1. Hanahan, D. and Weinberg, R.A. (2000) The hallmarks of cancer. Cell 100, 57-70
2. Ruoslati, E. (2000) Targeting tumor vasculature with homing peptides from phage display. Semin. Cancer Biol. 10, 435-442
3. Ruoslati, E. (2002) Specialization of tumor vasculature. Nat. Rev. Cancer 2, 83-90
4. Padera, T.P. et al. (2002) Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 296, 1883-1886
5. Alitalo, K. and Carmeliet, P. (2002) Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 1, 219-227
6. Maniotis, A.J. et al. (1999) Vascular channel formation by human melanoma cells in vivo and in vitro: vasculogenic mimicry. Am. J. Pathol. 155, 739-752
7. Hashizume, H. et al. (2000) Opening between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 156, 1363-1380
8. Hellstrom, M. et al. (2001) Lack of pericytes leads to endothelial hyperplasia and abnormal vascular morphogenesis. J. Cell Biol. 153, 543-553
9. Carmeliet, P. and Jain, R.K. (2000) Angiogenesis in cancer and other diseases. Nature 407, 249-257
10. Ferrara, N. and Alitalo, K. (1999) Clinical applications of angiogenic growth factors and their inhibitors. Nat. Med. 5, 1359-1364
11. Richard, D.E. et al. (2001) Angiogenesis and G-protein-coupled receptors: signals that bridge the gap. Oncogene 20, 1556-1562
12. Rubanyi, G.M. and Polokoff, M.A. (1994) Endothelins: molecular biology, biochemistry, pharmacology, physiology and pathophysiology. Pharmacol. Rev. 46, 325-415
13. Fujitani, Y. et al. (1992) Autocrine receptors for endothelins in the primary culture of endothelial cells of human umbilical vein. FEBS Lett. 298, 79-83
14. Saijonmaa, O. et al. (1992) Endothelin-1 stimulates its own synthesis in human endothelial cells. Biochem. Biophys. Res. Commun. 188, 286-291
15. Flynn, M.A. et al. (1998) Endothelin B receptors on human endothelial and smooth muscle cells show equivalent binding pharmacology. J. Cardiovasc. Pharmacol. 32, 106-116
16. 125I]-ET-1 binding to the atherosclerotic human coronary artery. Br. J. Pharmacol. 112, 386-389
17. Pedram, A. et al. (1997) Vasoactive peptides modulate vascular endothelial cell growth factor production and endothelial cell proliferation and invasion. J. Biol. Chem. 272, 17097-17103
18. Bagnato, A. et al. (1997) Activation of mitogenic signaling by endothelin-1 in ovarian carcinoma cells. Cancer Res. 57, 1306-1311
19. Daub, H. et al. (1996) Role of transactivation of the EGF receptor in signal by G-protein-coupled receptors. Nature 379, 557-559
20. Vacca, F. et al. (2000) Transactivation of the epidermal growth factor receptor in endothelin-l-induced mitogenic signaling in human ovarian carcinoma cells. Cancer Res. 60, 5310-5317
21. Del Bufalo, D. et al. (2002) Endothelin-1 protects ovarian carcinoma cells against paclitaxel-induced apoptosis: requirement for AKT activation. Mol. Pharmacol. 61, 524-532
22. Morbidelli, L. et al. (1995) Proliferation and migration of endothelial cells is promoted by endothelins via activation of ETB receptors. Am. J. Physiol. 269, H685-H695
23. Noiri, E. et al. (1997) Permissive role of nitric oxide in endothelininduced migration of endothelial cells. J. Biol. Chem. 272, 1747-1752
24. Noiri, E. et al. (1998) Podokinesis in endothelial cell migration: role of NO. Am. J. Physiol. 274, C236-C244
25. Wren, A. et al. (1993) Endothelin-3 mediated proliferation of wounded human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 196, 369-375
26. Dawas, K. et al. (1999) Angiogenesis in cancer: the role of endothelin-1. Ann. R. Coll. Surg. Engl. 81, 306-310
27. Salani, D. et al. (2000) Endothelin-1 induces an angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Am. J. Pathol. 157, 1703-1711
28. Bagnato, A. et al. (2001) Endothelin receptor blockade inhibits proliferation of Kaposi's sarcoma cells. Am. J. Pathol. 158, 841-847
29. Ribatti, D. et al. (1999) Human erythropoietin induces a proangiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 93, 2627-2639
30. Hu, D. et al. (1996) Comparative studies of the angiogenic activity of vasoactive intestinal peptide, endothelins-1 and -3 and angiotensin II in a rat sponge model. Br. J. Pharmacol. 117, 545-551
31. Bek, E.L. and Mc Millen, M.A. (2000) Endothelins are angiogenic. J. Cardiovasc. Pharmacol. 36, S135-S139
32. Cruz, A. et al. (2001) Endothelin-1, a regulator of angiogenesis in the chick chorioallantoic membrane. J. Vasc. Res. 38, 536-545
33. Shichiri, M. et al. (1997) Endothelin-1 as an autocrine/paracrine apoptosis survival factor for endothelial cells. Hypertension 30, 1198-1203
34. Wu-Wong, J.R. et al. (1997) Endothelin attenuates apoptosis in human smooth muscle cells. Biochem. J. 328, 733-737
35. Shichiri, M. et al. (2000) Endothelin-1 inhibits apoptosis of vascular smooth muscle cells induced by nitric oxide and serum-deprivation via MAP kinase pathway. Arterioscler. Thromb. Vasc. Biol. 20, 989-997
36. Yancopoulos, G.D. et al. (2000) Vascular-specific growth factors and blood vessel formation. Nature 407, 242-248
37. Matsuura, A. et al. (1998) Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression. Hypertension 32, 89-95
38. Okuda, Y. et al. (1998) Hypoxia and endothelin-1 induce VEGF production in human vascular smooth muscle cells. Life Sci. 63, 477-484
39. Yamashita, K. (2001) Molecular regulation of the endothelin-1 gene by hypoxia. Contributions of hypoxia-inducible factor-1 activator protein1, GATA-2 and p300/CBP. J. Biol. Chem. 276, 12645-12653
40. Molet, S. et al. (2000) Chemokine and cytokine-induced expression of endothelin-1 and endothelin converting enzyme 1 in endothelial cells. J. Aller. Clin. Immunol. 105, 333-338
41. Bagnato, A. and Catt, K.J. (1998) Endothelins as autocrine regulators of tumor cell growth. Trends Endocrinol. Metab. 9, 378-383
42. Pirtskhalaishvili, G. and Nelson, J.B. (2002) The endothelin receptor: a novel target for anticancer therapy. Am. J. Cancer 1, 3-8
43. Stiles, J.D. et al. (1997) Correlation of endothelin-1 and transforming growth factor β1 with malignancy and vascularity in human gliomas. J. Neuropathol. Exp. Neurol. 56, 435-439
44. Egidy, G. et al. (2000) The endothelin system in human glioblastoma. Lab. Invest. 80, 1681-1689
45. Egidy, G. et al. (2000) Modulation of human colon tumor-stromal interactions by the endothelin system. Am. J. Pathol. 157, 1863-1874
46. Asham, E. et al. (2001) Increased endothelin-1 in colorectal cancer and reduction of tumor growth by ETA receptor antagonist. Br. J. Cancer 85, 1759-1763
47. Kopetz, E.S. et al. (2002) Endothelin-1 as a target for therapeutic intervention in prostate cancer. Invest. New Drugs 20, 173-182
48. Kozawa, O. et al. (2000) Endothelin-1 induces vascular endothelial growth factor synthesis in osteoblasts. Involvement of p38 mitogenactivated protein kinase. Cell. Signal. 12, 375-380
49. Ahmed, S.I. et al. (2000) Studies on the expression of endothelin, its receptor subtypes and converting enzymes in lung cancer and in human bronchial epithelium. Am. J. Respir. Cell Mol. Biol. 22, 422-431
50. Fagan, K.A. et al. (2001) Role of endothelin-1 in lung disease. Respir. Res. 2, 90-101
51. Varda-Bloom, N. (2001) Tissue-specific gene therapy directed to tumor angiogenesis. Gene Ther. 8, 819-827
52. Bagnato, A. et al. (1999) Expression of endothelin 1 and endothelin A receptor in ovarian carcinoma: evidence for an autocrine role in tumor growth. Cancer Res. 59, 720-727
53. Salani, D. et al. (2000) Role of endothelin-1 in neovascularization of ovarian carcinoma. Am. J. Pathol. 157, 1537-1547
54. Spinella, S. et al. (2002) Endothelin-1 induces vascular endothelial growth factor by increasing hypoxia-inducible factor-1α in ovarian carcinoma cells. J. Biol. Chem. 277, 27850-27855
55. Harris, A.L. (2002) Hypoxia: a key regulatory factor in tumor growth. Nat. Rev. Cancer 2, 38-47
56. Semenza, G.L. (2002) HIF-1 and tumor progression: pathophysiology and therapeutics. Trends Mol. Med. 8, 562-567
57. Birner, P. et al. (2001) Expression of hypoxia-inducible factor 1α in epithelial ovarian tumors: its impact on prognosis and on response to chemotherapy. Clin. Cancer Res. 7, 1661-1668
58. Bagnato, A. et al. (1995) Autocrine actions of endothelin-1 as a growth factor in human ovarian carcinoma cells. Clin. Cancer Res. 59, 720-727
59. Rosanò, L. et al. (2001) Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells. Cancer Res. 61, 8340-8346
60. A selective endothelin antagonist, in humans. Br. J. Clin. Pharmacol. 49, 562-573
61. Salani, D. et al. (2002) ABT 627, a potent endothelin receptor A antagonist, inhibits ovarian carcinoma growth in vitro. Clin. Sci. 103, 318S-321S
62. Rosanò, L. et al. (2000) Inhibition of tumor growth and angiogenesis by ABT-627 an endothelin receptor A antagonist in ovarian carcinoma xenografts. Proc. Am. Assoc. Cancer Res. 41, 327
63. Sood, A.K. et al. (2002) The embryonic-like properties of aggressive human tumor cells. J. Soc. Gynecol. Investig. 9, 2-9
64. Carducci, M.A. et al. (2002) Atrasentan, an endothelin-receptor antagonist for refractory adenocarcinomas: safety and pharmacokinetics. J. Clin. Oncol. 20, 2171-2180